Aurinia Announces Results of Annual General Meeting

Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the nine incumbent directors of the Company were elected at the Company’s annual general meeting held on June 2, 2020 (the “Meeting”).

Detailed results of the vote by proxy for the election of directors are provided below:

Nominee				Votes For (%)				Votes Withheld (%)
Election of Directors
George M. Milne				82.49%				17.51%
Peter Greenleaf				93.25%				6.75%
David R.W. Jayne				99.41%				0.59%
Joseph P. Hagan				88.55%				11.45%
Michael Hayden				99.27%				0.73%
Daniel G. Billen				99.59%				0.41%
R. Hector MacKay-Dunn				99.31%				0.69%
Jill Leversage				99.70%				0.30%
Timothy P. Walbert				76.23%				23.77%

All other matters voted on at the Meeting were also approved. Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.

About Voclosporin

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,600 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action. By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney. It has been shown to have a more predictable pharmacokinetic and pharmacodynamic relationship (potentially requires no therapeutic drug monitoring), an increase in potency (versus cyclosporine A), and an improved metabolic profile compared to legacy CNIs. Aurinia anticipates that upon regulatory approval, patent protection for voclosporin will be extended in the United States and certain other major markets, including Europe and Japan, until at least October 2027 under the Hatch-Waxman Act and comparable laws in other countries and until April 2028 with anticipated pediatric extension. Further, a U.S. patent has also been issued covering the voclosporin dosing protocol with a term extending to December 2037, if the FDA incorporates the dosing protocol used in both the AURA and AURORA trials into the product label.